반응식
[CH3:1][CH:2]([N:4]1[C:12]2[C:11]([O:13][CH3:14])=[CH:10][CH:9]=[C:8]([C:15]([OH:17])=O)[C:7]=2[CH:6]=[CH:5]1)[CH3:3].[NH2:18][CH2:19][C:20]1[C:21](=[O:30])[NH:22][C:23]([CH3:29])=[CH:24][C:25]=1[CH2:26][CH2:27][CH3:28].ON1C2N=CC=CC=2N=N1.C(Cl)CCl.CN1CCOCC1>O.CS(C)=O>[CH3:3][CH:2]([N:4]1[C:12]2[C:11]([O:13][CH3:14])=[CH:10][CH:9]=[C:8]([C:15]([NH:18][CH2:19][C:20]3[C:21](=[O:30])[NH:22][C:23]([CH3:29])=[CH:24][C:25]=3[CH2:26][CH2:27][CH3:28])=[O:17])[C:7]=2[CH:6]=[CH:5]1)[CH3:1]참가 물질
8
반응물 5
생성물 1
시약·촉매·용매 2
실험 절차
Added 1-(1-methylethyl)-7-(methyloxy)-1H-indole-4-carboxylic acid (160 mg, 0.686 mmol), 3-(aminomethyl)-6-methyl-4-propyl-2(1H)-pyridinone (186 mg, 0.857 mmol), 1-hydroxy-7-azabenzotriazole (187 mg, 1.372 mmol), EDC (263 mg, 1.372 mmol) and N-methylmorpholine (0.302 mL, 2.74 mmol) to DMSO (10 mL) and stirred mixture at RT for 16 h. Added 25 ml of water and stirred for 10 minutes. Filtered off solids and dried in vacuo. The solids were purified by column chromatography (Biotage; 0% to 15% gradient MeOH:DCM; 10 g-HP-silica gel column) to give 165 mg of 1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-7-(methyloxy)-1H-indole-4-carboxamide.
후처리
- stirringstirred for 10 minutes
- filtrationFiltered off solids
- customdried in vacuo
- customThe solids were purified by column chromatography (Biotage; 0% to 15% gradient MeOH:DCM; 10 g-HP-silica gel column)
출처 및 근거
- ORD 기록
- ord-2afcf149aed4450c94b1257efecfe8ae
- 출처 데이터셋
- uspto-grants-2013_09
- 특허 번호
- US08536179B2
연결된 노트
불러오는 중…